Design and development of BACE-1 inhibitors

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 4, 2004, Pages 536-556

  Cumming, Jared N ^a   Iserloh, Ulrich ^a   Kennedy, Matthew E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Secretase; Alzheimer's disease; Aspartyl protease inhibitors; BACE; Drug development; Memapsin; Neurodegenerative diseases; Patent literature

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1; BETA AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 INHIBITOR; ENZYME; ENZYME INHIBITOR; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; PROTEINASE; SECRETASE;

ALZHEIMER DISEASE; DISEASE COURSE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FATALITY; HUMAN; IC 50; NONHUMAN; REVIEW; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG INDUSTRY; DRUG SCREENING; ENZYMOLOGY; METHODOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; ENDOPEPTIDASES; HUMANS; MOLECULAR STRUCTURE;

EID: 4644229581     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Alzheimer's Disease - About Alzheimer's. American Health Assistance Foundation, Clarksburg, MD, USA. http://www.ahaf.org/alzdis/about/adabout.htm
2. Z. Selkoe DJ, Podlisny MB: Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet (2002) 3:67-99.
3. Selkoe DJ: Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev (2001) 81(2):741-766. A comprehensive review of Aβ protein and AD.
4. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science (2002) 297(5580):353-356.
5. Glenner GG, Wong CW: Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 120(3):885-890.
6. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M: Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nat Neurosci (1998) 1(5):355-358.
7. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich B, Finch C et al: Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 21(3):383-421.
8. Hutton M, Perez-Tur J, Hardy J: Genetics of Alzheimer's disease. Essays Biochem (1998) 33:117-131.
9. St George-Hyslop PH: Molecular genetics of Alzheimer's disease. Biol Psychiatry (2000) 47(3):183-199.
10. Patterson D, Gardiner K, Kao FT, Tanzi R, Watkins P, Gusella JF: Mapping of the gene encoding the β-amyloid precursor protein and its relationship to the Down syndrome region of chromosome 21. Proc Natl Acad Sci USA (1988) 85(21):82B6-8270.
11. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Tumer S et al: Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 276(24):21562-21570.
12. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemes J, Donaldson T, Gillespie F, Guido T et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature (1995) 373(6514):523-527.
13. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S et al: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 4(1):97-100.
14. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science (1996) 274(5284):99-102.
15. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA et al: Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38(4):547-554. Clinical follow-up of a small cohort of Aβ-immunized AD patients.
16. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349(6311):704-706.
17. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y et al: β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286(5440):735-741. Description of expression cloning of BACE-1.
18. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon NL, Hong J, Jacobson-Croak K et al: Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature (1999) 402(6761):537-540. Description of the biochemical purification, sequencing and cloning of BACE-1.
19. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB et al: Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature (1999) 402(6761):533-537. Description of the identification of BACE-1 through database mining.
20. Hussain I, Powell DJ, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS et al: Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci (1999) 14(6):419-427.
21. Vassar R: The β-secretase, BACE: A prime drug target for Alzheimer's disease. J Mol Neurosci (2001) 17(2):157-170.
22. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J: Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science (2000) 290(5489):150-153.
23. Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, Hui JO, Bennett BD, Kahn S, Ross S, Burgess T, Katta V et al: Characterization of Alzheimer's β-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem (2000) 275(28):21099-21106.
24. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottolenghi S, Taramelli R: The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett (2000) 468(1):59-64.
25. Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, Vassar R: Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem (2000) 275(27):20647-20651.
26. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR, Tew DG, Meek TD, Chapman C, Schneider K, Ratcliffe SJ et al: ASP1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site. Mol Cell Neurosci (2000) 16(5):609-619.
27. Yan R, Munzner JB, Shuck ME, Bienkowski MJ: BACE2 functions as an alternative α-secretase in cells. J Biol Chem (2001) 276(36):34019-34027.
28. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H: BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc Natl Acad Sci USA (2000) 97(17):9712-9717.
29. Basi G, Frigon NL, Barbour R, Doan T, Gordon G, McConlogue L, Sinha S, Zeller M: Antagonistic effects of β-site amyloid precursor protein-cleaving enzymes 1 and 2 on β-amylold peptide production in cells. J Biol Chem (2003) 278:31512-31520.
30. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Koster A, Hess B, Evers M, von Figura K, Peters C: Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J(1995) 14(15):3599-3608.
31. Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y, Schulz-Schaeffer W, Watanabe T, Waguri S, Kametaka S, Shibata M et al: Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci (2000) 20(18):6898-6906.
32. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC: BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat Neurosci (2001) 4(3):233-234.
33. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L et al:. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci (2001) 4(3):231-232. First description of BACE-1 knockout mice.
34. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K et al: BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: Implications for Alzheimer's disease therapeutics. Hum Mol Genet (2001) 10(12):1317-1324. Detailed characterization of BACE-1 knockout mice.
35. Harper AJ, Harrison SM, Morrison AD, Austin AA, Dingwall C: BACE 1 and 2 double knockout mice are indistinguishable from wild type littermate controls. Abstr Soc Neurosci (2003) 33:Abs 842.12.
36. Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B: The cell adhesion protein P-selectin glycopratein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem (2003) 278(49):48713-48719.
37. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H: Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem (2002) 277:4687-4693. Thorough enzymatic comparison of BACE-1 with other aspartic proteases.
38. Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y: Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA (2001) 98(24):13554-13559.
39. Matayoshi ED, Wang GT, Krafft GA, Erickson J: Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science (1990) 247(4945):954-958.
40. Kennedy ME, Wang W, Song L, Lee J, Zhang L, Wong G, Wang L, Parker E: Measuring human β-secretase (BACE1) activity using homogeneous time-resolved fluorescence. Anal Biochem (2003) 319(1):49-55.
41. Wolfe MS: Secretase targets for Alzheimer's disease: Identification and therapeutic potential. J Med Chem (2001 ) 44(13):2039-2060. Broad perspective on the proteolytic enzymes involved in AD and issues related to drug development.
42. Ghosh AK, Hong L, Tang J: β-Secretase as a therapeutic target for inhibitor drugs. Curr Med Chem (2002) 9(11):1135-1144.
43. Lahiri DK, Farlow MR, Greig NH, Sambamurti K: Current drug targets for Alzheimer's disease treatment. Drug Dev Res (2002) 56(3):267-281.
44. Conway KA, Baxter EW, Felsenstein KM, Reitz AB: Emerging β-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Design (2003) 9(6):427-447.
45. Schmidt B: Aspartic proteases involved in Alzheimer's disease. ChemBioChem (2003) 4(5):366-378.
46. John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL: Human β-secretase (BACE) and BACE inhibitors. J Med Chem (2003) 46(22):4625-4630.
47. Citron M: β-Secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol Sci (2004) 25(2):92-97.
48. Ghosh AK, Shin D, Downs D, Koelsch G, Lin X, Ermolieff J, Tang J: Design of potent inhibitors for human brain memapsin 2 (β-secretase). J Am Chem Soc (2000) 122:3522-3523.
49. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J: Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science (2000) 290(5489):150-153.
50. Turner RT 3rd, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, Tang J, Castenheira P, Ghosh A: Subsite specificity of memapsin 2 (β-Secretase): Implications for inhibitor design. Biochemistry (2001) 40(34):10001-10006. First published X-ray crystal structure of BACE-1 inhibitor (OM99-2) complexed to recombinant BACE-1 protein.
51. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, Hong L, Loy JA, Nguyen C, Koelsch G, Ermolieff J et al: Structure-based design: Potent inhibitors of human brain memapsin 2 (β-secretase). J Med Chem (2001) 44(18):2865-2868.
52. Hong L, Turner RT 3rd, Koelsch G, Shin D, Ghosh AK, Tang J: Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00-3. Biochemistry (2002) 41(36):10963-10967.
53. Hu J, Cwi CL, Smiley DL, Timm D, Erickson JA, McGee JE, Yang HC, Mendel D, May PC, Shapiro M, McCarthy JR: Design and synthesis of statine-containing BACE inhibitors. Bioorg Med Chem Lett (2003) 13(24):4335-4339.
54. Anonymous: Statine-derived tetrapeptide Inhibitors of β-secretase. Expert Opin Ther Patents (2001) 11(6):1047-1050.
55. Lamar J, Hu J, Bueno AB, Yang HC, Guo D, Copp JD, McGee J, Gitter B, Timm D, May P, McCarthy J et al: Phe -Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg Med Chem Lett (2004) 14(1):239-243.
56. Tung JS, Davis DL, Anderson JP, Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED, John V: Design of substrate-based inhibitors of human β-secretase. J Med Chem (2002) 45(2):259-262.
57. Shuto D, Kasai S, Kimura T, Liu P, Hidaka K, Hamada T, Shibakawa S1 Hayashi Y, Hattori C, Szabo B, Ishiura S et al: KMI-008, a novel β-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: Design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett (2003) 13(24):4273-4276.
58. Kimura T, Shuto D, Kasai S, Liu P, Hidaka K, Hamada T, Hayashi Y, Hattori C, Asai M, Kitazume S, Saido TC et al: KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett (2004) 14(6):1527-1531.
59. Tamamura H, Kato T, Otaka A, Fujii N: Synthesis of potent β-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies. Org Biomol Chem (2003) 1(14):2468-2473.
60. Hom RK, Fang LY, Mamo S, Tung JS, Guinn AC, Walker DE, Davis DL, Gailunas AF, Thorsett ED, Sinha S, Knops JE et al: Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human β-secretase. J Med Chem (2003) 46(10):1799-1802.
61. Hom RK, Gailunas AF, Mamo S, Fang LY, Tung JS, Walker DE, Davis D, Thorsett ED, Jewett NE, Moon JB, John V: Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human β-secretase. J Med Chem (2004) 47(1):158-164.
62. Brady SF, Singh S, Crouthamel MC, Holloway MK, Cobum CA, Garsky VM, Bogusky M, Pennington MW, Vacca JP, Hazuda D, Lai MT: Rational design and synthesis of selective BACE-1 inhibitors. Bioorg Med Chem Lett (2004) 14(3):601-604.
63. Konvalinka J, Litera J, Weber J, Vondrasek J, Hradilek M, Soucek M, Pichova I, Majer P, Strop P, Sedlacek J, Heuser AM et al: Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus prateinase. Eur J Biochem (1997) 250(2):559-566. Review discussing the finding that the magnitude of potency shift from (S)-hydroxyl to (R)-hydroxyl was dependent on the P2' substituent.
64. Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ, Wasserman ZR, Liu RQ, Covington MB, Magolda RL, Newton RC et al: Discovery of N-hydroxy-2-(2-oxo-3- pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg Med Chem Lett (2003) 13(12):2035-2040.
65. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grutter MG: Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol (2000) 7(7):493-504.
66. Goschke R, Cohen NC, Wood JM, Maibaum J: Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin. Bioorg Med Chem Lett (1997) 7(21):2735-2740.
67. Reid RC, March DR, Dooley MJ, Bergman DA, Abbenante G, Fairlie DP: A novel bicyclic enzyme inhibitor as a consensus peptidomimetic for the receptor-bound conformations of twelve peptidic inhibitors of HIV-1 protease. J Am Chem Soc (1996) 118:8511-8517.
68. Culler R, Binggeli A, Breu V, Bur D, Fischli W, Hirth G, Jenny C, Kansy M, Montavon F, Muller M, Deiner C et al: Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg Med Cnem Lett (1999) 9(10):1403-1408. Describes, along with reference [69], the discovery and development of novel piperidines as renin inhibitors.
69. Vieira E, Binggeli A, Breu V, Bur D, Fischli W, Guller R, Hirth G, Marki HP, Muller M, Oefner C, Scalone M et al: Substituted piperidines - highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg Med Chem Lett (1999) 9(10):1397-1402. Describes, along with reference [68], the discovery and development of novel piperidines as renin inhibitors.
70. Jeon SY, Bae K, Seong YH, Song KS: Green tea catechins as a BACE-1 (β-Secretase) inhibitor. Bioorg Med Chem Lett (2003) 13(22):3905-3908.